Precision BioSciences Stock
Precision BioSciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael Amoroso
- Employees
- 67
- Market cap
- $159 M
- IPO
- 28/03/2019
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic…
Precision BioSciences stock: price history
1D
-6.5%
1W
-14.1%
1M
-13.0%
6M
-26.8%
YTD
+38.7%
1Y
-13.1%
2Y
-36.0%
5Y
-98.0%
10Y
–
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~4% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 12/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Precision BioSciences
Analyst assessment of Precision BioSciences
PRICE TARGET LOW
US$20.00
CONSENSUS
US$20.00
MEDIAN
US$20.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
9
BUY
3
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 03/08/2026
Precision BioSciences stock metrics
P/E
-2.07
P/B
3.29
EV/EBITDA
-2.04
RETURN ON EQUITY
-72.1%
NET MARGIN
0.0%
DEBT/EQUITY
0.62
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
92.2%
FLOAT SHARES
25,451,945
AVG. DAILY VOLUME (30D)
257,341
Insider transactions (SEC)
Frankel Stanley
Germano Geno J
Brown Melinda
Frankel Stanley
Germano Geno J
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Precision BioSciences stock
What does Precision BioSciences do?
Precision BioSciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael Amoroso, the company employs around 67 people.
The IPO was on 28/03/2019; the stock trades on NASDAQ under the ticker DTIL.
What do analysts say about Precision BioSciences stock?
12 analysts rate the stock, the consensus is Buy (as of 03/08/2026).
The average price target is US$20.00, ranging from US$20.00 to US$20.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does Precision BioSciences report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 4% stronger than usual.
Does Precision BioSciences pay a dividend?
No, Precision BioSciences currently does not pay a dividend.
Which stocks are comparable to Precision BioSciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Precision BioSciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Precision BioSciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.